Generated by AI
Femasys Inc. is a biomedical company focused on women’s reproductive health. The company develops and commercializes accessible, minimally invasive, in-office therapeutic and diagnostic products designed to address unmet needs in fertility care, birth control, and gynecologic testing. Its portfolio includes FemVue for fallopian tube assessment, FemCath for selective tube evaluation, FemCerv for endocervical tissue sampling, FemBloc for non-surgical permanent birth control, and FemaSeed for assisted insemination. Femasys also offers related products and technologies used by physicians and women’s healthcare providers in office-based settings. Headquartered in Suwanee, Georgia, Femasys serves both U.S. and international markets with a focus on improving reproductive healthcare delivery.
Website3950 Johns Creek Court
Suwanee, GA, 30024
United States
The latest articles about FEMY.
$30 million private placement supports commercial team build-out to drive U.S. sales growth; Q3 U.S. sales increased slightly despite significant funding constraints prior to mid-August financingATLANTA, Nov. 13, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announces its financ
ATLANTA, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announced today the appointment of John Moorhead to its Board of Directors as a board designee in connection with the Company’s August 2026 private placement. Mr. Moorhead brings more than two decades of experience
Summary of Oct 16's posts. Generated by AI.
Summary of Aug 19's posts. Generated by AI.
First in a planned network of specialty pharmacy partnerships provides medication coordination and preferred pricing for OB/GYNs and their patientsATLANTA, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announced today an agreement with SandsRx Pharmacy, marking the firs
Summary of Oct 17's posts. Generated by AI.
Summary of Aug 19's posts. Generated by AI.
Investors talking about FEMY also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.